Transaction in Own Shares

 
TIDMNVOB 
 
Novo Nordisk A/S - Share repurchase programme 
 
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in 
accordance with the provisions of the European Commission's regulation no 
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. 
 
Under the programme Novo Nordisk will repurchase B shares for an amount up to 
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010. 
 
 
Since the announcement as of 8 February 2010, the following transactions have 
been made under the programme: 
 
                        Number of shares Average purchase        Transaction 
                                               price       value, 
                                                                     DKK 
 
 Accumulated, last               435,000                            162,272,753 
 announcement 
 
 08 February 2010                 90,000          373.8999           33,650,991 
 
 09 February 2010                 90,000          374.0000           33,660,000 
 
 10 February 2010                 90,000          374.0290           33,662,610 
 
 11 February 2010                 90,000          378.7490           34,087,410 
 
 12 February 2010                 90,000          385.0110           34,650,990 
 
 Accumulated under the           885,000                            331,984,754 
 programme 
 
 
Transactions related to Novo Nordisk's incentive programmes have resulted in a 
net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010 
to 12 February 2010. The shares in these transactions were not part of the Safe 
Harbour repurchase programme. 
 
With the transactions stated above, Novo Nordisk owns a total of 31,281,948 
treasury shares, corresponding to 5.0% of the share capital. The total amount of 
shares in the company is 620,000,000 including treasury shares. 
 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In 
addition, Novo Nordisk has a leading position within areas such as haemostasis 
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk 
manufactures and markets pharmaceutical products and services that make a 
significant difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 
countries, and markets its products in 179 countries. Novo Nordisk's B shares 
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed 
on the New York Stock Exchange under the symbol 'NVO'. For more information, 
visit novonordisk.com. 
 
Further information: 
 
 
 Media:                                  Investors: 
 
 
 Elin K Hansen                           Klaus Bülow Davidsen 
 
 Tel: [phone]                    Tel: [phone] 
 
 [e-mail]                     [e-mail] 
 <mailto:[e-mail]>            <mailto:[e-mail]> 
 
 
                                         Kasper Roseeuw Poulsen 
 
                                         Tel: [phone] 
 
                                         [e-mail] 
                                         <mailto:[e-mail]> 
 
 
 In North America:                       In North America: 
 
 Sean Clements                           Hans Rommer 
 
 Tel: [phone]                  Tel: [phone] 
 
 [e-mail]                    [e-mail] 
 <mailto:[e-mail]>           <mailto:[e-mail]> 
 
 
Company Announcement no 9 / 2010 
 
 
 
 
[HUG#1384418] 
 
 
 
 
 
    Company Announcement no 9 2010: http://hugin.info/2013/R/1384418/343190.pdf